PCI Biotech and MDimune announce research collaboration agreement
05 Enero 2022 - 12:00AM
PCI Biotech and MDimune announce research collaboration agreement
Oslo, Norway and Seoul, South Korea 5 January,
2022 – PCI Biotech (OSE: PCIB), a Norwegian cancer focused
biopharmaceutical company and MDimune Inc. (“MDimune”), a private
South Korean biotech company developing innovative drug delivery
technologies for modifying cellular and disease processes in many
areas of human disease, today announced a preclinical research
collaboration that would offer several opportunities for future
development.
Commenting on the announcement, Per Walday, CEO
of PCI Biotech, said: “We are very pleased to initiate a
collaboration with MDimune. This collaboration is an additional
mark of interest from a cutting-edge biotech company developing
therapies with emerging advanced technologies, with a large
potential in future medicine."
Seung Wook Oh, Chief Scientific Officer of
MDimune added: “We are excited to launch this collaboration with
PCI Biotech. PCI Biotech’s versatile photochemical technologies
have the potential to enhance several aspects of our technologies,
to make future therapies more efficient and more specific.”
Please see the attachment for the full press
release.
Contact
information: Per
Walday,
CEO pw@pcibiotech.noMobile:
+47 917 93 429
Forward-looking
statements This
announcement may contain forward-looking statements, which as such
are not historical facts, but are based upon various assumptions,
many of which are based, in turn, upon further assumptions. These
assumptions are inherently subject to significant known and unknown
risks, uncertainties and other important factors. Such risks,
uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking
statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
This information is subject to the disclosure
requirements pursuant to section 5-12 of the Norwegian Securities
Trading Act.
- PR PCI Biotech_MDImune collaboration 5 Jan 2022
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De May 2023 a May 2024